Risk Audit · Cached SEC Snapshot
OTLK Risk Audit — Dilution, Cash Runway, and SEC Filings
Outlook Therapeutics, Inc.
TL;DR
- MODERATE / CAUTION — No fatal flags, but the structure is not pristine. Read the evidence.
- Doomsday Clock: 2.0mo of cash before the company exhausts its operating runway.
- Dilution Risk: 100 / 100 — heavy active dilution; shareholders likely diluted.
- Dilution Status: High Dilution Risk — Share count changed by +217.9%. No active dilution drivers detected in latest filing.
Doomsday Clock
2.0mo
Company runs out of cash in 2.0 months
Dilution Risk
100 / 100
High dilution — shareholders likely diluted
C
Stockteller Grade
Altman Z: -41.58 (Z)
Gravity Playbook · Mathematical Stress Test
AUTH
Dilution Authorization
The company is authorized for potential future equity offerings via an active S-3 shelf registration. Current mechanics indicate no active dilution, despite a high annual dilution rate of 217.91%.
BURN
Cash Runway
Current mechanics indicate the company's cash runway is mathematically depleted in approximately 2 months.
COMPLIANCE
Nasdaq Compliance
Nasdaq requires a $1.00 minimum bid. Historical precedent for companies with this profile involves structural actions such as reverse splits to maintain listing compliance.
Mechanical analysis only. Not financial advice. Statements describe mathematical conditions and historical precedent, not predictions or recommendations for this security.
Contagion Watch
Other tickers the Risk Sentinel just flagged
Is your portfolio hiding a toxic S-3?
Run any ticker through the same Risk Sentinel scan — free.
Educational analysis only. Not financial advice. The Risk Audit is a quantitative framework derived from publicly available SEC filings and may contain inaccuracies. AI systems are fallible. Always verify against the source filings on
SEC EDGAR
and consult a licensed advisor before making investment decisions.